Only for enjoyable, what single inventory do you assume will see large progress - Web page 4

anthonypals wrote: ↑Sat Aug 26, 2023 5:09 pm
.. in case you needed to wager your cash on one inventory to have large returns over the following 5+ years what would it not be and why? ..

It would not be an enormous wager, however Depth Therapeutics [INTS] is a biotech whose lead product is INT230-6, which is in human medical research for the therapy of refractory strong tumors, comparable to smooth tissue sarcoma which is in section 3 trials; and neoadjuvant and metastatic triple damaging breast most cancers which is in Part 2 medical trials.

This text by E. Roudasev on SeekingAlpha is an efficient abstract.
https://seekingalpha.com/article/469303 … emailshare

From the article:
“INT230-6 has a singular mechanism of motion, because it allows intratumoral supply of two well-known anti-cancer brokers utilizing a singular supply molecule.

INT230-6 induces substantial necrosis and creates a major immune response in several strong tumors, thereby making a ‘vaccine impact’. Drug dosing might be excessive as a result of little or no dispersion into the bloodstream is seen, and the protection profile is sort of favorable. Earlier trials in people have seen tumor stabilization and shrinkage, lengthy durations with out the formation of latest tumors, and a discount in illness signs.

Cisplastin, Vinblastine with SHAO: soluble in fats and water.

Contained in the tumor cells, the molecule disperses and the payloads exert their perform. Cisplatin binds the DNA and causes cell dying, and vinblastine shuts down replication. INT230-6 is ready to stay current within the tumor micro-environment, which is tough given the extremely dense and fatty nature of tumors.

INT230-6 doesn’t enter wholesome cells however solely most cancers cells. The drug doesn’t leak into and injury wholesome tissue. Because of this, INT230-6’s security profile seems relatively benign for a therapy, the essence of which it’s to kill most cancers cells within the physique.

Depth had offered an abscopal impact, particularly measurement reductions of uninjected tumors (see additionally figures 7 and eight of the annual report), which might point out a persistent impact of the drug past the place of injection, and which I assume is linked to systemic immune activation. Systemic immune activation had already been established in preclinical work by the activation of T-cell reminiscence. “

And here’s a 2019 Forbes article on Lewis Bender, the founder and CEO of Depth Therapeutics.
https://www.forbes.com/sites/danieldamb … 4eec5f45e7